MedTrace Logo

Dose-response Study of OPC-12759 Ophthalmic Suspension

NCT00234078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2014-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the dose-response of OPC-12759 ophthalmic suspension in dry eye patients.

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

0.5% OPC-12759

DRUG

1% OPC-12759

DRUG

2% OPC-12759

DRUG

placebo

Sponsors & Collaborators

  • Otsuka Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Satoshi Oshima · Dermatologicals & Ophthalmologicals Division

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2006-04-30
Completion
2007-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00234078 on ClinicalTrials.gov